Labcorp's Beat Was Price, Not Volume — and Quest Diagnostics's 14.5% Volume Surge Is a Contract, Not a Demand Wave

The decomposition is where the headline breaks down. Diagnostics Laboratories revenue rose 6.5% to $2.95 billion, but organic growth of 4.4% was 3.1 points of price/mix and 1.3 points of volume, with the remaining 2.1 points coming from acquisitions and other items. Applied to last year's base, volume contributed roughly $36 million of a $247 million enterprise revenue increase. Clinical utilization explains about one dollar in seven of the quarter's revenue gain.

Two other lines point the same way. Central laboratories grew 11.5% within $867 million of Biopharma Laboratory Services revenue — that is pharmaceutical research spending, not US patient demand — and free cash flow rose 47% to $412 million as operating cash flow reached $564 million against $152 million of capital expenditure. Guidance for full-year adjusted EPS went to $18.30–$18.70. Margin and cash carried the quarter, not the requisition counter.

Quest Diagnostics produced the quarter's loudest volume number — revenue up 10.0% to $3.10 billion on requisition volume up 14.5% — but management attributed the 4.2% drop in revenue per requisition to the Corewell Health and Fresenius contracts, which add test volume at low prices per requisition. Strip those two relationships out and Quest still grew volume about 5%, with revenue up 6.6% and revenue per requisition up 1.7%. Same quarter, same country, same end market: Quest's volume ran about four times Labcorp's.

Valuation now reflects the print rather than the bridge. At the Oct 27 close of $331.17, Labcorp traded at about 18 times the midpoint of its raised guidance; the roughly 10% move takes that toward 20 times, against Quest at about 21.5 times its own guidance midpoint. On enterprise value the ranking inverts: Labcorp at roughly 17.9 times trailing EBITDA to Quest's 14.0 times, with net leverage of 3.3 times against 2.4 times and a 4.4% free cash flow yield against 5.1%. Labcorp is the more levered, more enterprise-expensive name in a market where it is growing volume slowest.

The coverage shock is real, but it is being priced at the payer and hospital layer, not at the test-order counter. HCA Healthcare took an estimated $400 million pretax hit in the third quarter from a payer-mix shift toward uninsured patients who had lost exchange coverage, expects $550 million to $650 million less Medicaid supplemental net benefits in 2027, and guides 2027 volume growth of 2% to 3%. Molina Healthcare reports Medicaid membership down about 4.5% year to date against a 93.0% Medicaid medical care ratio, while UnitedHealth Group served 6.695 million Medicaid members at Sept 30 and reported an 88.4% medical care ratio, down from 89.9% but helped by $610 million of favorable prior-period reserve development. Coverage is deteriorating faster than the volume of tests being ordered.

Tempus AI is the cleanest expression of the AI-diagnostics claim: it guided 2026 revenue to $1.595 billion to $1.605 billion, about 25% growth, and posted second-quarter revenue of $382.5 million, up 22%. Labcorp's own AI spending runs the other way — automation, robotics, digital pathology and productivity programs — and surfaces as a sixth consecutive quarter of enterprise margin progression, with Diagnostics Laboratories adjusted operating margin at 16.7% and Biopharma Laboratory Services at 18.3%. AI is showing up in the labs' margin line, not in their requisition counts.

With organic volume at 1.3%, growth has to come from somewhere else, and it does. Labcorp spent $941 million on acquisitions in the twelve months to September 2026 against $1.287 billion of free cash flow, funded with $500 million of net new debt. Across 2023 to 2025 it spent $2.08 billion on deals while generating $3.18 billion of free cash flow. Roughly two-thirds of three years of free cash flow went into buying growth rather than funding volume.

On Sept 21, 2026, CMS released preliminary Clinical Laboratory Fee Schedule rates for 2027 through 2029; the American Hospital Association says the 2027 preliminary rates would cut payments by as much as 15% on nearly 1,200 laboratory services. Labcorp's own estimate of the 2027 Medicare reduction is about $125 million — under 1% of enterprise revenue — with incremental 2028 and 2029 effects management called meaningfully less. The company reaffirmed its 5% to 8% revenue compound growth outlook through 2029 at its Sept 10 Investor Day and again in an8-K two days after CMS published the preliminary rates. The 2027 cut is small enough to absorb and drawn from too little data to be final.

The near-term calendar is crowded and the long-term test is slow. Four dates and disclosures matter more than anything else, and only one of them tests the demand question directly. The evidence for AI-driven volume will not arrive until somebody's requisition count moves.

Putting the layers together: utilization is growing low single digits, price and mix are doing the heavy lifting, acquisitions are filling what volume cannot, and reimbursement is the one variable that can take a point of price back in 2027. That is a different picture from the one the tape painted on Oct 28. Labcorp is executing well into a market whose test volume is barely growing.

For investors, the practical implication is that the lab print is best read as a pricing and share gauge, not a utilization gauge, and that the AI-diagnostics narrative is being credited with demand that the requisition counters do not show. The cleanest way to express a view on US healthcare demand right now is not the national labs' volume lines but the payer layer — medical care ratios, Medicaid membership and hospital payer mix — which is where the deterioration actually shows up. Read the payers for demand, and the labs for pricing power.